Let me be very clear. You have four phases when you build a plant. You have the design phase, the construction phase, the certification phase and the production phase.
I think we should all rejoice, first, as parliamentarians, that Novavax has chosen Canada. When I talked to the CEO.... They could have gone to about seven or eight countries where they already have manufacturing facilities, but they chose Canada, which is good news.
What I did say—and the Prime Minister—is that we expect construction to be completed by the end of the summer. Then you have the period of certification, which could be a couple of months, because, as you know, this is about good manufacturing practices. This is governed by Health Canada in accordance with its processes. Canadians would understand that we want to go fast but that we want to make sure that we respect all the health and safety protocols. Following that, we would go into production.
What I did say is that we would be producing a vaccine before the end of the year in that facility, in Royalmount. We are very pleased, I must say, and we should—you and I and every Canadian—think that having Novavax.... We were lucky because, in a way, the manufacturing process that we have in Royalmount is compatible with the Novavax vaccine. The second thing that made the CEO choose Canada was speed and, obviously, a very stable, predictable, secure supply market. I think that's good news because we need to be prudent and resilient for the future.